This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sasaki, H. Articles by Louis, D. N. Search for Related Content PubMed PubMed Citation Articles by Sasaki, H. Articles by Louis, D. N.

DMBT1 Polymorphisms

Relationship to Malignant Glioma Tumorigenesis¹

Molecular Neuro-Oncology and Pathology Laboratories, Department of Pathology and Neurosurgical Service, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts 02129 [H. S., D. N. L.]; Department of Biostatistics, Harvard School of Public Health, Boston, Massachusetts 02115 [R. A. B.]; and Departments of Clinical Neurological Sciences and Oncology, University of Western Ontario and London Regional Cancer Centre, London, Ontario, N6A4L6 Canada [J. G. C.]

The deleted in malignant brain tumors 1 (DMBT1) gene on 10q25-26 is a candidate tumor suppressor gene in malignant gliomas, but its role is controversial, e.g., some DMBT1 homozygous deletions reflect unmasking of constitutional deletion polymorphisms by 10q loss. To clarify the role of DMBT1 in gliomagenesis, we investigated three reported deletion hot spots. Homozygous deletions at DMBT1 repeat 2-4 to 2-7 were found in 10 of 73 gliomas with 10q loss, but all 10 deletions reflected unmasking of constitutional hemizygous deletions. Alleles bearing deletion 2-4/2-7 were not selected significantly for by 10q loss, with retention of only 10 of 16 deleted alleles. No homozygous deletion was detected at locus 74k in the 5' upstream region of DMBT1, and four tightly linked polymorphisms were found around this region; chromosome 10q loss randomly affected alleles with or without the variant sequences around locus 74k. Moreover, no significant selection pressure was detected for the haplotype with both deletion 2-4/2-7 and 5' polymorphisms. There was no segregation of deletion 2-4/2-7 in glioma patients compared with unrelated individuals from reference families but a suggestion of a difference in the distribution of the 5' polymorphisms between the reference individuals and glioma patients. Constitutional polymorphisms at DMBT1 repeat 2-9/2-10 appeared common in patients with both benign brain tumors and gliomas. A homozygote for both the 2-4/2-7 deletion and the 5' polymorphisms had a glioma arise at a typical age and without an apparent family cancer predisposition. These data suggest that DMBT1 polymorphisms are not likely primary targets of 10q loss in malignant gliomas and do not support a major role for DMBT1 in gliomagenesis.

This article has been cited by other articles:

				A. C. Blackburn, L. Z. Hill, A. L. Roberts, J. Wang, D. Aud, J. Jung, T. Nikolcheva, J. Allard, G. Peltz, C. N. Otis, et al. Genetic Mapping in Mice Identifies DMBT1 as a Candidate Modifier of Mammary Tumors and Breast Cancer Risk Am. J. Pathol., June 1, 2007; 170(6): 2030 - 2041. [Abstract] [Full Text] [PDF]

				W. Kang, O. Nielsen, C. Fenger, G. Leslie, U. Holmskov, and K. B.M. Reid Induction of DMBT1 expression by reduced ERK activity during a gastric mucosa differentiation-like process and its association with human gastric cancer Carcinogenesis, June 1, 2005; 26(6): 1129 - 1137. [Abstract] [Full Text] [PDF]

				S. Tynan, E. Pacia, D. Haynes-Johnson, D. Lawrence, M. R. D'Andrea, J.-Z. Guo, S. Lundeen, and G. Allan The Putative Tumor Suppressor Deleted in Malignant Brain Tumors 1 Is an Estrogen-Regulated Gene in Rodent and Primate Endometrial Epithelium Endocrinology, March 1, 2005; 146(3): 1066 - 1073. [Abstract] [Full Text] [PDF]

				D. Mihaila, J. A. Gutierrez, M. L. Rosenblum, I. F. Newsham, O. Bogler, and S. A. Rempel Meningiomas: Analysis of Loss of Heterozygosity on Chromosome 10 in Tumor Progression and the Delineation of Four Regions of Chromosomal Deletion in Common with Other Cancers Clin. Cancer Res., October 1, 2003; 9(12): 4435 - 4442. [Abstract] [Full Text] [PDF]

				D. Mihaila, M. Jankowski, J. A. Gutierrez, M. L. Rosenblum, I. F. Newsham, O. Bogler, and S. A. Rempel Meningiomas: Loss of Heterozygosity on Chromosome 10 and Marker-Specific Correlations with Grade, Recurrence, and Survival Clin. Cancer Res., October 1, 2003; 9(12): 4443 - 4451. [Abstract] [Full Text] [PDF]

				P. Leuraud, L. Aguirre-Cruz, K. Hoang-Xuan, E. Criniere, M-L. Tanguy, J-L. Golmard, M. Kujas, J-Y. Delattre, and M. Sanson Telomerase reactivation in malignant gliomas and loss of heterozygosity on 10p15.1 Neurology, June 10, 2003; 60(11): 1820 - 1822. [Abstract] [Full Text] [PDF]